RESUMO
BACKGROUND AND OBJECTIVES: Prolonged cardiac monitoring (PCM) increases atrial fibrillation (AF) detection after ischemic stroke, but access is limited, and it is burdensome for patients. Our objective was to assess whether midregional proatrial natriuretic peptide (MR-proANP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) could classify people who are unlikely to have AF after ischemic stroke and allow better targeting of PCM. METHODS: We analyzed people from the Biomarker Signature of Stroke Aetiology (BIOSIGNAL) study with ischemic stroke, no known AF, and ≥3 days cardiac monitoring. External validation was performed in the Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) study of 28 days of cardiac monitoring in people with ischemic stroke or transient ischemic attack and no known AF. The main outcome is no AF detection. We assessed the discriminatory value of MR-proANP and NT-proBNP combined with clinical variables to identify people with no AF. A decision curve analysis was performed with combined data to determine the net reduction in people who would undergo PCM using the models based on a 15% threshold probability for AF detection. RESULTS: We included 621 people from the BIOSIGNAL study. The clinical multivariable prediction model included age, NIH Stroke Scale score, lipid-lowering therapy, creatinine, and smoking status. The area under the receiver-operating characteristic curve (AUROC) for clinical variables was 0.68 (95% CI 0.62-0.74), which improved with the addition of log10MR-proANP (0.72, 0.66-0.78; p = 0.001) or log10NT-proBNP (0.71, 0.65-0.77; p = 0.009). Performance was similar for the models with log10MR-proANP vs log10NT-proBNP (p = 0.28). In 239 people from the PRECISE study, the AUROC for clinical variables was 0.68 (0.59-0.76), which improved with the addition of log10NT-proBNP (0.73, 0.65-0.82; p < 0.001) or log10MR-proANP (0.79, 0.72-0.86; p < 0.001). Performance was better for the model with log10MR-proANP vs log10NT-proBNP (p = 0.03). The models could reduce the number of people who would undergo PCM by 30% (clinical and log10MR-proANP), 27% (clinical and log10NT-proBNP), or 20% (clinical only). DISCUSSION: MR-proANP and NT-proBNP help classify people who are unlikely to have AF after ischemic stroke. Measuring MR-proANP or NT-proBNP could reduce the number of people who need PCM by 30%, without reducing the amount of AF detected. TRIAL REGISTRATION INFORMATION: NCT02274727; clinicaltrials.gov/study/NCT02274727.
Assuntos
Fibrilação Atrial , Fator Natriurético Atrial , Biomarcadores , AVC Isquêmico , Peptídeo Natriurético Encefálico , Fragmentos de Peptídeos , Humanos , Fibrilação Atrial/sangue , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/complicações , Masculino , Feminino , Idoso , Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Pessoa de Meia-Idade , Fator Natriurético Atrial/sangue , Biomarcadores/sangue , AVC Isquêmico/sangue , AVC Isquêmico/diagnóstico , Estudos de Coortes , Idoso de 80 Anos ou mais , Acidente Vascular Cerebral/sangue , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/etiologiaRESUMO
BACKGROUND: Patients with COPD are often affected by loss of bone mineral density (BMD) and osteoporotic fractures. Natriuretic peptides (NP) are known as cardiac markers, but have also been linked to fragility-associated fractures in the elderly. As their functions include regulation of fluid and mineral balance, they also might affect bone metabolism, particularly in systemic disorders such as COPD. RESEARCH QUESTION: We investigated the association between NP serum levels, vertebral fractures and BMD assessed by chest computed tomography (CT) in patients with COPD. METHODS: Participants of the COSYCONET cohort with CT scans were included. Mean vertebral bone density on CT (BMD-CT) as a risk factor for osteoporosis was assessed at the level of TH12 (AI-Rad Companion), and vertebral compression fractures were visually quantified by two readers. Their relationship with N-terminal pro-B-type natriuretic peptide (NT-proBNP), Mid-regional pro-atrial natriuretic peptide (MRproANP) and Midregional pro-adrenomedullin (MRproADM) was determined using group comparisons and multivariable analyses. RESULTS: Among 418 participants (58% male, median age 64 years, FEV1 59.6% predicted), vertebral fractures in TH12 were found in 76 patients (18.1%). Compared to patients without fractures, these had elevated serum levels (p ≤ 0.005) of MRproANP and MRproADM. Using optimal cut-off values in multiple logistic regression analyses, MRproANP levels ≥ 65 nmol/l (OR 2.34; p = 0.011) and age (p = 0.009) were the only significant predictors of fractures after adjustment for sex, BMI, smoking status, FEV1% predicted, SGRQ Activity score, daily physical activity, oral corticosteroids, the diagnosis of cardiac disease, and renal impairment. Correspondingly, MRproANP (p < 0.001), age (p = 0.055), SGRQ Activity score (p = 0.061) and active smoking (p = 0.025) were associated with TH12 vertebral density. INTERPRETATION: MRproANP was a marker for osteoporotic vertebral fractures in our COPD patients from the COSYCONET cohort. Its association with reduced vertebral BMD on CT and its known modulating effects on fluid and ion balance are suggestive of direct effects on bone mineralization. TRIAL REGISTRATION: ClinicalTrials.gov NCT01245933, Date of registration: 18 November 2010.
Assuntos
Fator Natriurético Atrial , Biomarcadores , Densidade Óssea , Doença Pulmonar Obstrutiva Crônica , Fraturas da Coluna Vertebral , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fator Natriurético Atrial/sangue , Biomarcadores/sangue , Densidade Óssea/fisiologia , Estudos de Coortes , Fraturas por Osteoporose/sangue , Fraturas por Osteoporose/epidemiologia , Fraturas por Osteoporose/diagnóstico , Fraturas por Osteoporose/diagnóstico por imagem , Precursores de Proteínas/sangue , Doença Pulmonar Obstrutiva Crônica/sangue , Doença Pulmonar Obstrutiva Crônica/epidemiologia , Doença Pulmonar Obstrutiva Crônica/diagnóstico , Fraturas da Coluna Vertebral/sangue , Fraturas da Coluna Vertebral/epidemiologia , Fraturas da Coluna Vertebral/diagnóstico por imagemRESUMO
Background: Myxomatous mitral valve disease (MMVD) is prevalent in dogs. Specialized diagnostics (radiography and echocardiography) may be unavailable in some veterinary settings. Cardiac biomarkers offer potential alternatives. Aim: This study evaluated the diagnostic value of N-terminal fragments of pro-brain natriuretic peptides (NT-proBNPs), atrial natriuretic peptides (ANPs), and cardiac troponin I (cTnI) levels in dogs with MMVD. Methods: 69 dogs with MMVD (asymptomatic and symptomatic) and 19 healthy controls were assessed. Biomarker levels were measured using commercial kit rapid tests. Results: Our results showed that the median NT-proBNP level in the symptomatic group was higher than those in the asymptomatic (p < 0.001) and control (p < 0.001) groups. Moreover, the median NT-proBNP level in the asymptomatic group was higher than that in the control group (p < 0.001). The cTnI level in the control group was lower than those in the asymptomatic (p = 0.039) and symptomatic (p = 0.001) groups. No statistically significant difference in the cTnI level was noted between the asymptomatic and symptomatic groups. The best cutoff value of the NT-proBNP level to differentiate the normal controls from dogs with MMVD with or without congestive heart failure was > 505.65 pmol/l [sensitivity, 76.8%; specificity, 89.5%; and area under the curve (AUC), 0.862]. The suggested cutoff value of the NT-proBNP level to differentiate symptomatic MMVD from asymptomatic MMVD was >787.65 pmol/l (sensitivity, 78.38%; specificity, 72.55%; and AUC, 0.792). Conclusion: NT-proBNP and cTnI may serve as point-of-care tests for dyspneic dogs, aiding MMVD assessment where specialized diagnostics are limited.
Assuntos
Fator Natriurético Atrial , Biomarcadores , Doenças do Cão , Peptídeo Natriurético Encefálico , Fragmentos de Peptídeos , Troponina I , Cães , Animais , Doenças do Cão/diagnóstico , Doenças do Cão/sangue , Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Masculino , Biomarcadores/sangue , Feminino , Troponina I/sangue , Fator Natriurético Atrial/sangue , Sensibilidade e Especificidade , Estudos de Casos e Controles , Doenças das Valvas Cardíacas/veterinária , Doenças das Valvas Cardíacas/sangue , Doenças das Valvas Cardíacas/diagnósticoRESUMO
An angiotensin receptor/neprilysin inhibitor (ARNI), a heart failure treatment, is a combination drug made up of sacubitril, a neprilysin inhibitor, and valsartan, a vascular receptor blocker. No human or veterinary studies regarding the effect of ARNI on renal haemodynamics in the absence of cardiac or renal issues exist. Therefore, we investigated the effect of ARNI on renal haemodynamics in five healthy dogs. ARNI was administered to all five dogs at an oral dose of 20 mg/kg twice daily for 4 weeks. Renal haemodynamics were assessed on the day before ARNI administration (BL), on Day 7, and on Day 28. The glomerular filtration rate (GFR) significantly increased on Day 28 compared to BL and Day 7, whereas renal plasma flow increased on Day 7 and Day 28 compared to BL. Systolic blood pressure significantly decreased between BL and Day 28. Plasma atrial natriuretic peptide (ANP) concentrations increased on Day 7 compared to BL. Additionally, ANP concentrations increased on Day 28 in three of the five dogs. Different ANP concentrations were observed in the remaining two dogs. Both urine output volume and heart rate remained relatively stable and did not exhibit significant change. In conclusion, ARNI may enhance renal haemodynamics in healthy dogs. ARNI could be a valuable drug for treating both heart and kidney disease in dogs.
Assuntos
Antagonistas de Receptores de Angiotensina , Hemodinâmica , Rim , Neprilisina , Valsartana , Animais , Cães , Neprilisina/antagonistas & inibidores , Hemodinâmica/efeitos dos fármacos , Antagonistas de Receptores de Angiotensina/farmacologia , Rim/efeitos dos fármacos , Rim/metabolismo , Valsartana/farmacologia , Masculino , Aminobutiratos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Fator Natriurético Atrial/sangue , Taxa de Filtração Glomerular/efeitos dos fármacos , Feminino , Combinação de Medicamentos , Compostos de Bifenilo/farmacologia , Tetrazóis/farmacologia , Circulação Renal/efeitos dos fármacosRESUMO
OBJECTIVES: There is currently limited understanding of the relationship between copeptin, the midregional portion of proadrenomedullin (MRproADM) and the midregional fragment of the N-terminal of proatrial natriuretic peptide (MRproANP), and arterial disorders. Toe brachial index (TBI) and aortic pulse wave velocity (aPWV) are established parameters for detecting arterial disorders. This study evaluated whether copeptin, MRproADM, and MRproANP were associated with TBI and aPWV in patients with type 2 diabetes with no history of cardiovascular disease (CVD). METHODS: In the CARDIPP study, a cross-sectional analysis of 519 patients with type 2 diabetes aged 55-65 years with no history of CVD at baseline, had complete data on copeptin, MRproADM, MRproANP, TBI, and aPWV was performed. Linear regression analysis was used to investigate the associations between conventional CVD risk factors, copeptin, MRproADM, MRproANP, TBI, and aPWV. RESULTS: Copeptin was associated with TBI (ß-0.0020, CI-0.0035- (-0.0005), p = 0.010) and aPWV (ß 0.023, CI 0.002-0.044, p = 0.035). These associations were independent of age, sex, diabetes duration, mean 24-hour ambulatory systolic blood pressure, glycated hemoglobin A1c, total cholesterol, estimated glomerular filtration rate, body mass index, and active smoking. CONCLUSIONS: Plasma copeptin may be a helpful surrogate for identifying individuals at higher risk for arterial disorders. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT010497377.
Assuntos
Adrenomedulina , Biomarcadores , Diabetes Mellitus Tipo 2 , Glicopeptídeos , Humanos , Glicopeptídeos/sangue , Estudos Transversais , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/diagnóstico , Diabetes Mellitus Tipo 2/complicações , Masculino , Pessoa de Meia-Idade , Feminino , Biomarcadores/sangue , Idoso , Adrenomedulina/sangue , Fator Natriurético Atrial/sangue , Rigidez Vascular , Fragmentos de Peptídeos/sangue , Análise de Onda de Pulso , Angiopatias Diabéticas/sangue , Angiopatias Diabéticas/diagnóstico , Angiopatias Diabéticas/fisiopatologia , Precursores de Proteínas/sangue , Medição de Risco , Valor Preditivo dos TestesRESUMO
Osteocrin (OSTN) is an endogenous protein sharing structural similarities with the natriuretic peptides [NPs; atrial (ANP), B-type (BNP) and C-type (CNP) NP], which are hormones known for their crucial role in maintaining pressure/volume homeostasis. Osteocrin competes with the NPs for binding to the receptor involved in their clearance (NPR-C). In the present study, having identified, for the first time, the major circulating form of OSTN in human and ovine plasma, we examined the integrated haemodynamic, endocrine and renal effects of vehicle-controlled incremental infusions of ovine proOSTN (83-133) and its metabolism in eight conscious normal sheep. Incremental i.v. doses of OSTN produced stepwise increases in circulating concentrations of the peptide, and its metabolic clearance rate was inversely proportional to the dose. Osteocrin increased plasma levels of ANP, BNP and CNP in a dose-dependent manner, together with concentrations of their intracellular second messenger, cGMP. Increases in plasma cGMP were associated with progressive reductions in arterial pressure and central venous pressure. Plasma cAMP, renin and aldosterone were unchanged. Despite significant increases in urinary cGMP levels, OSTN administration was not associated with natriuresis or diuresis in normal sheep. These results support OSTN as an endogenous ligand for NPR-C in regulating plasma concentrations of NPs and associated cGMP-mediated bioactivity. Collectively, our findings support a role for OSTN in maintaining cardiovascular homeostasis.
Assuntos
GMP Cíclico , Hemodinâmica , Rim , Animais , Ovinos , Rim/metabolismo , GMP Cíclico/metabolismo , Hemodinâmica/efeitos dos fármacos , Hemodinâmica/fisiologia , Fator Natriurético Atrial/metabolismo , Fator Natriurético Atrial/sangue , Feminino , Peptídeo Natriurético Encefálico/metabolismo , Renina/metabolismo , Renina/sangue , AMP Cíclico/metabolismo , Peptídeo Natriurético Tipo C/metabolismo , Aldosterona/sangue , Aldosterona/metabolismo , Pressão Sanguínea/fisiologia , Pressão Sanguínea/efeitos dos fármacos , Peptídeos Natriuréticos/metabolismo , NatriureseAssuntos
Fator Natriurético Atrial , Biomarcadores , AVC Embólico , AVC Isquêmico , Valor Preditivo dos Testes , Humanos , AVC Isquêmico/etiologia , AVC Isquêmico/diagnóstico , Biomarcadores/sangue , Masculino , Fator Natriurético Atrial/sangue , Feminino , AVC Embólico/etiologia , AVC Embólico/diagnóstico , Idoso , Prognóstico , Pessoa de Meia-IdadeRESUMO
Natriuretic peptides (NP) have multiple actions benefitting cardiovascular and metabolic health. Although many of these are mediated by Guanylyl Cyclase (GC) receptors NPR1 and NPR2, their role and relative importance in vivo is unclear. The intracellular mediator of NPR1 and NPR2, cGMP, circulates in plasma and can be used to examine relationships between receptor activity and tissue responses targeted by NPs. Plasma cGMP was measured in 348 participants previously recruited in a multidisciplinary community study (CHALICE) at age 50 years at a single centre. Associations between bio-active NPs and bio-inactive aminoterminal products with cGMP, and of cGMP with tissue response, were analysed using linear regression. Mediation of associations by NPs was assessed by Causal Mediation Analysis (CMA). ANP's contribution to cGMP far exceed those of other NPs. Modelling across three components (demographics, NPs and cardiovascular function) shows that ANP and CNP are independent and positive predictors of cGMP. Counter intuitively, findings from CMA imply that in specific tissues, NPR1 responds more to BNP stimulation than ANP. Collectively these findings align with longer tissue half-life of BNP, and direct further therapeutic interventions towards extending tissue activity of ANP and CNP.
Assuntos
GMP Cíclico , Receptores do Fator Natriurético Atrial , Humanos , Receptores do Fator Natriurético Atrial/metabolismo , Pessoa de Meia-Idade , Masculino , Feminino , GMP Cíclico/metabolismo , Peptídeos Natriuréticos/metabolismo , Fator Natriurético Atrial/metabolismo , Fator Natriurético Atrial/sangueRESUMO
BACKGROUND: Retinopathy of prematurity (ROP) is a major complication in preterm infants. We assessed if plasma levels of midregional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET1) serve as early markers for subsequent ROP development in preterm infants <32 weeks gestation. METHODS: Prospective, two-centre, observational cohort study. MR-proANP and CT-proET1 were measured on day seven of life. Associations with ROP ≥ stage II were investigated by univariable and multivariable logistic regression models. RESULTS: We included 224 infants born at median (IQR) 29.6 (27.1-30.8) weeks gestation and birth weight of 1160 (860-1435) g. Nineteen patients developed ROP ≥ stage II. MR-proANP and CT-proET1 levels were higher in these infants (median (IQR) 864 (659-1564) pmol/L and 348 (300-382) pmol/L, respectively) compared to infants without ROP (median (IQR) 299 (210-502) pmol/L and 196 (156-268) pmol/L, respectively; both P < 0.001). MR-proANP and CT-proET1 levels were significantly associated with ROP ≥ stage II in univariable logistic regression models and after adjusting for co-factors, including gestational age and birth weight z-score. CONCLUSIONS: MR-proANP and CT-proET1 measured on day seven of life are strongly associated with ROP ≥ stage II in very preterm infants and might improve early prediction of ROP in the future. IMPACT: Plasma levels of midregional pro-atrial natriuretic peptide and C-terminal pro-endothelin-1 measured on day seven of life in very preterm infants show a strong association with development of retinopathy of prematurity ≥ stage II. Both biomarkers have the potential to improve early prediction of retinopathy of prematurity. Vasoactive peptides might allow to reduce the proportion of screened infants substantially.
Assuntos
Fator Natriurético Atrial , Biomarcadores , Endotelina-1 , Retinopatia da Prematuridade , Humanos , Retinopatia da Prematuridade/sangue , Retinopatia da Prematuridade/diagnóstico , Recém-Nascido , Biomarcadores/sangue , Estudos Prospectivos , Fator Natriurético Atrial/sangue , Feminino , Masculino , Endotelina-1/sangue , Recém-Nascido Prematuro/sangue , Idade Gestacional , Fragmentos de Peptídeos/sangue , Modelos Logísticos , Precursores de Proteínas/sangueRESUMO
Abstract INTRODUCTION: Pulmonary arterial hypertension (PAH) is a serious pulmonary circulation disease caused by several etiologies, including schistosomiasis. The present study retrospectively evaluated the clinical and hemodynamic characteristics of patients with schistosomal PAH (PAH-Sch) compared to those of non-Sch PAH patients (non-Sch PAH). METHODS: Patients treated at the Pronto-Socorro Cardiológico de Pernambuco and diagnosed by right cardiac catheterization were divided into PAH-Sch and non-Sch PAH groups. Their socio-demographic and clinical characteristics, N-terminal-pro B-type natriuretic peptide (NT-proBNP), and echocardiography and hemodynamic parameters were retrospectively reviewed. RESULTS: Among the included 98 patients (mean age, 45 ± 14 years; 68 women [69.4%]), we found 56 PAH-Sch and 42 non-Sch PAH. The age distribution was heterogeneous in the PAH-Sch group, with patients predominantly ranging from 50-59 (p <0.004). Dyspnea was the most common symptom, reported by 92 patients (93.8%), and commonly present for over two years prior to diagnosis. Clinical symptoms were similar in both groups, with no differences in functional class, pulmonary artery systolic pressure (p = 0.102), 6-minute walk test score (p = 0.234), NT-proBNP serum levels (p = 0.081), or hemodynamic parameters. CONCLUSIONS: Patients with PAH-Sch present clinical, laboratory, and hemodynamic profiles similar to those with PAH resulting from other etiologies of poor prognosis. PAH is an important manifestation of schistosomiasis in endemic regions that is often diagnosed late.
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Precursores de Proteínas/sangue , Esquistossomose/complicações , Fator Natriurético Atrial/sangue , Hipertensão Arterial Pulmonar/etiologia , Fatores Socioeconômicos , Ecocardiografia , Biomarcadores/sangue , Estudos Retrospectivos , Hipertensão Arterial Pulmonar/sangue , Pessoa de Meia-IdadeRESUMO
RESUMO Objetivo: Avaliar a presença de hiponatremia e natriurese, bem como suas associações com o fator natriurético atrial em pacientes de neurocirurgia. Métodos: Foram incluídos 30 pacientes submetidos à ressecção de tumor intracraniano e à clipagem de aneurisma cerebral. Os níveis plasmáticos e urinários de fator natriurético atrial foram medidos durante os períodos pré e pós-operatório. Resultados: Hiponatremia esteve presente em 63,33% dos pacientes, particularmente no primeiro dia pós-operatório. Observou-se natriurese em 93,33% dos pacientes, principalmente no segundo dia pós-operatório. Os níveis plasmáticos de fator natriurético atrial estavam aumentados em 92,60% dos pacientes em pelo menos um dos dias pós-operatórios, mas não houve associação estatisticamente significante entre fator natriurético atrial e sódio plasmático, e entre fator natriurético atrial e sódio urinário. Conclusão: Após neurocirurgia, na maior parte dos pacientes, estiveram presentes hiponatremia e natriurese; contudo, o fator natriurético atrial não pôde ser considerado diretamente responsável por tais alterações nos pacientes neurocirúrgicos. Provavelmente, há o envolvimento de outros fatores natriuréticos.
ABSTRACT Objective: To evaluate the presence of hyponatremia and natriuresis and their association with atrial natriuretic factor in neurosurgery patients. Methods: The study included 30 patients who had been submitted to intracranial tumor resection and cerebral aneurism clipping. Both plasma and urinary sodium and plasma atrial natriuretic factor were measured during the preoperative and postoperative time periods. Results: Hyponatremia was present in 63.33% of the patients, particularly on the first postoperative day. Natriuresis was present in 93.33% of the patients, particularly on the second postoperative day. Plasma atrial natriuretic factor was increased in 92.60% of the patients in at least one of the postoperative days; however, there was no statistically significant association between the atrial natriuretic factor and plasma sodium and between the atrial natriuretic factor and urinary sodium. Conclusion: Hyponatremia and natriuresis were present in most patients after neurosurgery; however, the atrial natriuretic factor cannot be considered to be directly responsible for these alterations in neurosurgery patients. Other natriuretic factors are likely to be involved.
Assuntos
Humanos , Masculino , Feminino , Adulto , Fator Natriurético Atrial/sangue , Procedimentos Neurocirúrgicos/métodos , Hiponatremia/epidemiologia , Natriurese/fisiologia , Período Pós-Operatório , Sódio/urina , Neoplasias Encefálicas/cirurgia , Aneurisma Intracraniano/cirurgia , Estudos Prospectivos , Período Pré-Operatório , Pessoa de Meia-IdadeRESUMO
Objective. To evaluate technical efficiency and potential presence of scale and scope economies in Mexican private medical units (PMU) that will improve management decisions. Materials and methods. We used data envelopment analysis methods with inputs and outputs for 2 105 Mexican PMU published in 2010 by the Instituto Nacional de Estadística y Geografía from the "Estadística de Unidades Médicas Privadas con Servicio de Hospitalización (PEC-6-20-A)" questionnaire. Results. The application of the models used in the paper found that there is a marginal presence of economies of scale and scope in Mexican PMU. Conclusions. PMU in Mexico must focus to deliver their services on a diversified structure to achieve technical efficiency.
Objetivo. Evaluar la eficiencia técnica y la presencia de potenciales economías de escala y alcance en unidades médicas privadas (UMP) mexicanas, de forma que sea posible establecer planes para la mejora de su gestión. Material y métodos. Se utilizó el método de Análisis Envolvente de Datos con información de insumos y productos para 2 105 UMP del año 2010 publicada por el Instituto Nacional de Estadística y Geografía a través del cuestionario denominado "Estadística de Unidades Médicas Privadas con Servicio de Hospitalización (PEC-6-20-A)". Resultados. La aplicación de los modelos encuentra una presencia marginal de economías de escala y alcance en las UMP mexicanas. Conclusiones. La operación de las UMP en México debe enfocarse a prestar servicios bajo un modelo diversificado para alcanzar mejores niveles de eficiencia técnica.
Assuntos
Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fator Natriurético Atrial/sangue , Proteínas do Tecido Nervoso/sangue , Disfunção Ventricular Esquerda/diagnóstico , Biomarcadores/sangue , Cateterismo Cardíaco , Estudos Transversais , Fragmentos de Peptídeos/sangue , Valor Preditivo dos Testes , Precursores de Proteínas/sangueRESUMO
Studies of body volume expansion have indicated that lesions of the anteroventral third ventricle and median eminence block the release of atrial natriuretic peptide (ANP) into the circulation. Detailed analysis of the lesions showed that activation of oxytocin (OT)-ergic neurons is responsible for ANP release, and it has become clear that activation of neuronal circuitry elicits OT secretion into the circulation, activating atrial OT receptors and ANP release from the heart. Subsequently, we have uncovered the entire functional OT system in the rat and the human heart. An abundance of OT has been observed in the early development of the fetal heart, and the capacity of OT to generate cardiomyocytes (CMs) has been demonstrated in various types of stem cells. OT treatment of mesenchymal stem cells stimulates paracrine factors beneficial for cardioprotection. Cardiovascular actions of OT include: i) lowering blood pressure, ii) negative inotropic and chronotropic effects, iii) parasympathetic neuromodulation, iv) vasodilatation, v) anti-inflammatory activity, vi) antioxidant activity, and vii) metabolic effects. OT actions are mediated by nitric oxide and ANP. The beneficial actions of OT may include the increase in glucose uptake by CMs and stem cells, reduction in CM hypertrophy, oxidative stress, and mitochondrial protection of several cell types. In experimentally induced myocardial infarction in rats, continuous in vivo OT delivery improves cardiac healing and cardiac work, reduces inflammation, and stimulates angiogenesis. Because OT plays anti-inflammatory and cardioprotective roles and improves vascular and metabolic functions, it demonstrates potential for therapeutic use in various pathologic conditions.
Assuntos
Animais , Humanos , Ratos , Fator Natriurético Atrial/sangue , Coração/fisiologia , Ocitocina/fisiologia , Receptores de Ocitocina/metabolismo , Cardiotônicos , Diferenciação Celular , Miócitos Cardíacos/metabolismo , Óxido Nítrico/metabolismo , Estresse Oxidativo/fisiologia , Transdução de Sinais/fisiologiaRESUMO
OBJECTIVES: Acute ST-elevation myocardial infarction is associated with ventricular dysfunction due to ischemia-induced progressive myocardial damage. The decrease in ventricular compliance causes left atrial dilatation and stretching of the atrial myocardium, which are the main stimuli for the secretion of atrial natriuretic peptide. The aim of this study was to evaluate left atrial dimensions and atrial natriuretic peptide levels in patients early after their first acute ST-elevation myocardial infarction and assess the probable interaction between coronary lesions and these measurements. METHODS: A total of 110 patients with acute myocardial infarction and 50 controls were studied. Plasma atrial natriuretic peptide was measured at admission. Left ventricular function, diameter, and volume index were evaluated using transthoracic echocardiography. Gensini and vessel scores of the patients who underwent coronary angiography were calculated. RESULTS: Plasma atrial natriuretic peptide in the patients with myocardial infarction was increased compared with that in controls (3.90±3.75 vs. 1.35±0.72 nmol/L, p<0.001). Although the left atrial diameter was comparable in patients and controls, the left atrial volume index was increased in patients with acute myocardial infarction (26.5±7.1 vs. 21.3±4.9 mL/m2, p<0.01). Multivariate regression analysis showed a strong independent correlation between the left atrial volume index and the plasma atrial natriuretic peptide level (β = 0.23, p = 0.03). CONCLUSIONS: The left atrial volume index and plasma atrial natriuretic peptide level were correlated in patients with acute myocardial infarction. .
Assuntos
Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Função do Átrio Esquerdo/fisiologia , Fator Natriurético Atrial/sangue , Infarto do Miocárdio/sangue , Infarto do Miocárdio/fisiopatologia , Volume Sistólico/fisiologia , Índice de Massa Corporal , Biomarcadores/sangue , Estudos de Casos e Controles , Angiografia Coronária , Ecocardiografia , Átrios do Coração/patologia , Átrios do Coração/fisiopatologia , Análise Multivariada , Estudos Prospectivos , Fatores de TempoRESUMO
FUNDAMENTO: A avaliação da função Ventricular Direita (VD) pelo ecocardiograma em pacientes com Tromboembolismo Pulmonar (TEP) é complexa, frequentemente qualitativa; o Doppler tecidual tem sido utilizado para avaliação semiquantitativa dessa câmara, com algumas limitações. OBJETIVO: Avaliar a função do VD no TEP pelo ecocardiograma com Doppler tecidual, complementando com o peptídeo atrial natriurético (BNP). MÉTODOS: Foram estudados pacientes com TEP pelo ecocardiograma com Doppler tecidual e BNP até 24 horas do diagnóstico, obtendo-se as velocidades miocárdicas (s'), strain, strain rate e índice de performance miocárdica do VD; disfunção do VD foi iagnosticada por hipocinesia da câmara, movimento anormal septal e relação VD/VE >1. De acordo com o BNP os pacientes foram divididos em Grupo I, BNP < 50 pg/mL e Grupo II, BNP > 50 pg/mL. RESULTADOS: De 118 pacientes, 100 (60 homens, idade = 55 ± 17 anos) foram analisados; observou-se disfunção do VD em 28%, mais frequentemente no grupo II (19 vs. 9 pacientes, p < 0,001). O grupo II era mais idoso (64 ± 19 vs. 50 ± 15 anos), apresentava menor velocidade de s' (10,5 ± 3,5 vs. 13,2 ± 3,1 cm/s) e maior pressão pulmonar (48 ± 11 vs. 35 ± 11 mmHg), p < 0,001 para todos. O ponto de corte de s' para disfunção do VD foi de 10,8 cm/s (especificidade = 85%, sensibilidade = 54%), com moderada correlação entre o BNP e a onda s'(r = -0,39). CONCLUSÃO: No TEP, a disfunção do VD pelo ecocardiograma se acompanha de elevação do BNP; apesar confirmar adequadamente a presença de disfunção do VD, o Doppler tecidual apresenta sensibilidade limitada para este diagnóstico.
BACKGROUND: Assessment of the right ventricular (RV) function by echocardiography in patients with pulmonary thromboembolism (PTE) is complex and frequently qualitative. Tissue Doppler has been used for the semiquantitative assessment of this chamber, although with some limitations. OBJECTIVE: To evaluate RV function in PTE using tissue-Doppler echocardiography, in addition to atrial natriuretic peptide (BNP). METHODS: Patients with PTE were studied using tissue-Doppler echocardiography and BNP up to 24 hours after diagnosis; myocardial velocities (s'), strain, strain rate and RV myocardial performance index were obtained. RV dysfunction was diagnosed by chamber hypokinesia, abnormal septal motion and a RV/LV ratio >1. According to their BNP levels, the patients were divided into Group I, BNP < 50 pg/mL and Group II, BNP > 50 pg/mL. RESULTS: Of 118 patients, 100 (60 men, age = 55 ± 17 years) were analyzed; RV dysfunction was observed in 28%, more frequently in group II (19 vs. 9 patients, p < 0.001). Patients in group II were older (64 ± 19 vs. 50 ± 15 years), and had lower s' velocity (10.5 ± 3.5 vs. 13.2 ± 3.1 cm/s), and higher pulmonary pressure (48 ± 11 vs. 35 ± 11 mmHg), p < 0.001. The cut-off point of s' for RV dysfunction was 10.8 cm/s (specificity = 85%, sensitivity = 54%), with moderate correlation between BNP and s' wave (r = -0.39). CONCLUSION: In PTE, RV dysfunction on echocardiography is accompanied by BNP elevation; although tissue-Doppler imaging adequately confirms the presence of RV dysfunction, it has a limited sensitivity for this diagnosis.
Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ecocardiografia Doppler/métodos , Embolia Pulmonar/fisiopatologia , Disfunção Ventricular Direita , Fator Natriurético Atrial/sangue , Pressão Sanguínea/fisiologia , Frequência Cardíaca/fisiologia , Variações Dependentes do Observador , Embolia Pulmonar/sangue , Curva ROC , Disfunção Ventricular Direita/sangue , Disfunção Ventricular Direita/fisiopatologiaRESUMO
OBJETIVO: Níveis de procalcitonina, midregional pro-atrial natriuretic peptide (MR-proANP, pró-peptídeo natriurético atrial midregional),, C-terminal provasopressin (copeptina), proteína C reativa (CRP) e escore do Sequential Organ Failure Assessment (SOFA) são associados a gravidade e descritos como preditores de desfechos na pneumonia associada a ventilação mecânica (PAVM). Este estudo procurou comparar o valor preditivo de mortalidade desses biomarcadores na PAVM. MÉTODOS: Estudo observacional com 71 pacientes com PAVM. Níveis de procalcitonina, MR-proANP, copeptina e PCR, bem como escore de SOFA foram obtidos no dia do diagnóstico de PAVM, designado dia zero (D0), e no quarto dia de tratamento (D4) Os pacientes receberam tratamento antimicrobiano empírico, com modificações baseadas nos resultados de cultura. Os pacientes que morreram antes de D28 foram classificados como não sobreviventes. RESULTADOS: Dos 71 pacientes, 45 sobreviveram. Dos 45 sobreviventes, 35 (77,8 por cento) receberam tratamento antimicrobiano adequado, comparados com 18 (69,2 por cento) dos 26 não sobreviventes (p = 0,57). Os sobreviventes apresentaram valores significativamente mais baixos em todos os biomarcadores estudados, inclusive no escore de SOFA (exceto PCR) em D0 e D4. Em D0 e D4, a área sob a curva ROC foi maior para procalcitonina. Em D0, MR-proANP teve a maior razão de verossimilhança positiva (2,71) e valor preditivo positivo (0,60), mas a procalcitonina apresentou o maior valor preditivo negativo (0,87). Em D4, a procalcitonina apresentou a maior razão de verossimilhança positiva (3,46), o maior valor preditivo positivo (0,66) e o maior valor preditivo negativo (0,93). CONCLUSIONS: Os biomarcadores procalcitonina, MR-proANP e copeptina podem predizer mortalidade na PAVM, assim como o escore de SOFA. A procalcitonina tem o maior poder preditivo de mortalidade na PAVM.
OBJECTIVE: Levels of procalcitonin, midregional pro-atrial natriuretic peptide (MR-proANP), C-terminal provasopressin (copeptin), and C-reactive protein (CRP), as well as Sequential Organ Failure Assessment (SOFA) scores, are associated with severity and described as predictors of outcome in ventilator-associated pneumonia (VAP). This study sought to compare the predictive value of these biomarkers for mortality in VAP. METHODS: An observational study of 71 patients with VAP. Levels of procalcitonin, MR-proANP, copeptin, and CRP, together with SOFA scores, were determined at VAP onset, designated day 0 (D0), and on day 4 of treatment (D4). Patients received empirical antimicrobial therapy, with modifications based on culture results. Patients who died before D28 were classified as nonsurvivors. RESULTS: Of the 71 patients evaluated, 45 were classified as survivors. Of the 45 survivors, 35 (77.8 percent) received appropriate antimicrobial therapy, compared with 18 (69.2 percent) of the 26 nonsurvivors (p = 0.57). On D0 and D4, the levels of all biomarkers (except CRP), as well as SOFA scores, were lower in eventual survivors than in eventual nonsurvivors. For D0 and D4, the area under the ROC curve was largest for procalcitonin. On D0, MR-proANP had the highest positive likelihood ratio (2.71) and positive predictive value (0.60), but procalcitonin had the highest negative predictive value (0.87). On D4, procalcitonin had the highest positive likelihood ratio (3.46), the highest positive predictive value (0.66), and the highest negative predictive value (0.93). CONCLUSIONS: The biomarkers procalcitonin, MR-proANP, and copeptin can predict mortality in VAP, as can the SOFA score. Procalcitonin alone has the greatest predictive power for such mortality.
Assuntos
Feminino , Humanos , Masculino , Biomarcadores/sangue , Insuficiência de Múltiplos Órgãos/mortalidade , Pneumonia Associada à Ventilação Mecânica/mortalidade , Área Sob a Curva , Fator Natriurético Atrial/sangue , Brasil/epidemiologia , Proteína C-Reativa/análise , Estudos de Coortes , Calcitonina/sangue , Glicopeptídeos/sangue , Insuficiência de Múltiplos Órgãos/sangue , Valor Preditivo dos Testes , Hormônios Peptídicos/sangue , Pneumonia Associada à Ventilação Mecânica/sangue , Precursores de Proteínas/sangue , Curva ROC , Índice de Gravidade de DoençaRESUMO
Las neumonías, tanto comunitarias como nosocomiales, constituyen una importante causa de morbimortalidad a nivel global y ocasionan además importantes costos sanitarios. Como en cualquier otro proceso infeccioso, una adecuada respuesta a la infección es un fenómeno complejo que requiere un apropiado y oportuno tratamiento antibiótico, así como una apropiada respuesta inflamatoria inicial para contener la proliferación y diseminación de los microorganismos, seguida por una respuesta antiinflamatoria compensatoria que restaure la homeostasis inicial. Recientes estudios han demostrado que una excesiva respuesta inflamatoria en sepsis y NAC severa puede asociarse con efectos deletéreos y peor pronóstico. Por otro lado, una exagerada respuesta antiinflamatoria puede tener efecto negativo en la resolución de la infección. Por lo tanto, una mejor comprensión de este delicado equilibrio proinflamatorio/antiinflamatorio y sus mediadores podrán ser de gran ayuda para valorar la presencia y gravedad de la neumonía así como su probable evolución. En estudios previos varios marcadores han sido ensayados: Proteína C reactiva (PCR), Procalcitonina (PCT), diversas interleuquinas (IL1, IL6, IL8 e IL10), factor de necrosis tumoral alfa (TNFalfa), etc., como marcadores de inflamación/infección, gravedad, fallo de tratamiento y pronóstico. La presente monografía tiene por objeto hacer una revisión sintética de la literatura reciente sobre el tema, tratando de explorar y objetivar fortalezas y debilidades de tales marcadores biológicos.
Community acquired and nosocomial pneumonia are considered a global health issue and a significant cause of morbility, mortality and important economic costs. As in other infectious diseases, an appropriate therapeutic response to the infection is a complex phenomenon that requires appropriate and timely antimicrobial treatment and acorrect initial inflammatory response to stop the microbial proliferation and dissemination, followed by an anti-inflammatory response to restore the initial homeostasis. Recently published studies have showed that exaggerated inflammatory response in sepsis and severe community acquired pneumonia may be associated with poorer outcomes. On the other hand, an exagerated inflammatory response may have a deleterious effect on the infection resolution. Consequently, a better understanding of the delicate balance inflammation/anti-inflammation and their mediators could be of great help to understand the presence and severity of pneumonia and even to predict its outcome. Several marker shave been used, including C-reactive protein (CRP), procalcitonin, several interleukines [IL1, IL6, IL8, IL10], tumor necrosis factor-alpha (TNF alfa), etc, as markers of inflammation /infection, severity, therapeutic failure, severity therapeutic failure and prognostic tool. This review was performed to summarize the observations of the more recent published data on this topic, trying to explore strengths and weaknesses of these markers.
Assuntos
Humanos , Adulto , Adulto Jovem , Pessoa de Meia-Idade , Infecções Comunitárias Adquiridas/diagnóstico , Biomarcadores/sangue , Pneumonia/diagnóstico , Calcitonina/sangue , Fator Natriurético Atrial/sangue , Líquido da Lavagem Broncoalveolar/química , Proteína C-Reativa/análiseRESUMO
We investigated the involvement of GABAergic mechanisms of the central amygdaloid nucleus (CeA) in unanesthetized rats subjected to acute isotonic or hypertonic blood volume expansion (BVE). Male Wistar rats bearing cannulas unilaterally implanted in the CeA were treated with vehicle, muscimol (0.2 nmol/0.2 µL) or bicuculline (1.6 nmol/0.2 µL) in the CeA, followed by isotonic or hypertonic BVE (0.15 or 0.3 M NaCl, 2 mL/100 g body weight over 1 min). The vehicle-treated group showed an increase in sodium excretion, urinary volume, plasma oxytocin (OT), and atrial natriuretic peptide (ANP) levels compared to control rats. Muscimol reduced the effects of BVE on sodium excretion (isotonic: 2.4 ± 0.3 vs vehicle: 4.8 ± 0.2 and hypertonic: 4.0 ± 0.7 vs vehicle: 8.7 ± 0.6 µEq·100 g-1·40 min-1); urinary volume after hypertonic BVE (83.8 ± 10 vs vehicle: 255.6 ± 16.5 µL·100 g-1·40 min-1); plasma OT levels (isotonic: 15.3 ± 0.6 vs vehicle: 19.3 ± 1 and hypertonic: 26.5 ± 2.6 vs vehicle: 48 ± 3 pg/mL), and ANP levels (isotonic: 97 ± 12.8 vs vehicle: 258.3 ± 28.1 and hypertonic: 160 ± 14.6 vs vehicle: 318 ± 16.3 pg/mL). Bicuculline reduced the effects of isotonic or hypertonic BVE on urinary volume and ANP levels compared to vehicle-treated rats. However, bicuculline enhanced the effects of hypertonic BVE on plasma OT levels. These data suggest that CeA GABAergic mechanisms are involved in the control of ANP and OT secretion, as well as in sodium and water excretion in response to isotonic or hypertonic blood volume expansion.
Assuntos
Animais , Masculino , Ratos , Tonsila do Cerebelo/efeitos dos fármacos , Bicuculina/farmacologia , Volume Sanguíneo/efeitos dos fármacos , Agonistas GABAérgicos/farmacologia , Antagonistas GABAérgicos/farmacologia , Muscimol/farmacologia , Tonsila do Cerebelo/fisiologia , Fator Natriurético Atrial/sangue , Bicuculina/administração & dosagem , Volume Sanguíneo/fisiologia , Diurese/efeitos dos fármacos , Diurese/fisiologia , Agonistas GABAérgicos/administração & dosagem , Antagonistas GABAérgicos/administração & dosagem , Muscimol/administração & dosagem , Ocitocina/sangue , Ratos Wistar , Sódio/urinaRESUMO
OBJETIVO: o estudo busca determinar a existência de associação entre a elevação da pressão arterial e os níveis plasmáticos dos peptídeos natriuréticos ANP e BNP, na gestaçäo complicada pela pré-eclâmpsia. MÉTODOS: em estudo transversal caso-controle, pareado por idade gestacional, 25 grávidas normotensas e 61 portadoras de pré-eclâmpsia foram avaliadas quanto ao nível da pressão arterial e às concentraçöes plasmáticas dos peptídeos natriuréticos ANP e BNP. Exames clínico e laboratoriais foram realizados para o diagnóstico de pré-eclâmpsia, sendo a pressäo arterial medida de forma näo invasiva. As dosagens hormonais foram obtidas por radioimunoensaio, após extraçäo em colunas Sep-pak C18. Os valores médios das concentraçöes plasmáticas do ANP e BNP foram comparados entre grupos com pressäo arterial progressivamente maiores. A correlaçäo entre os valores da pressäo arterial e os níveis plasmáticos do ANP e BNP no sangue materno foi também investigada pela de análise de regressäo no grupo completo de gestantes e em grupos específicos excluindo-se a hipertensäo anterior à gestaçäo e, em seguida, excluindo-se aquelas sem hipertensäo prévia. RESULTADOS: os valores plasmáticos de ANP foram 41.5±7.3, 78.4±13.1 e 89.2±13.4 pg/mL (p<0,00001) e os de BNP plasmático foram 79.5±15.8, 176.7±42.2 e 208.3±63.5 pg/mL (p=0,005), respectivamente, para os grupos de pressäo arterial média =107 mmHg, 107-139 mmHg e =140 mmHg. Verificou-se correlaçäo positiva entre as concentrações plasmáticas do ANP e os níveis pressóricos na pré-eclâmpsia, independente da existência de estado hipertensivo prévio à gestaçäo (p<0,0001 para pré-eclâmpsia e p<0,01 para pré-eclampsia sobreposta à hipertensäo arterial crônica), ao passo que as dosagens de BNP näo se mostraram associadas à pressão arterial no grupo com hipertensäo arterial prévia à gestação (p=0,004 para pré-eclâmpsia e p=0,18 para pré-eclampsia sobreposta à hipertensäo arterial crônica). CONCLUSÃO: o agravamento da hipertensäo na pré-eclâmpsia correlacionou-se com as concentraçöes séricas do ANP e BNP, embora os valores do BNP possam ser influenciados pela existência de estado hipertensivo prévio